Please ensure Javascript is enabled for purposes of website accessibility

Boston Scientific Q4 Income Climbs as Costs Fall

By Associated Press - Feb 4, 2014 at 12:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company said it expects to earn $0.35 to $0.40 per share in 2014.

NEW YORK (AP) -- Boston Scientific's net income nearly doubled in the fourth quarter as its costs decreased and sales improved for heart devices, nerve stimulation implants, and devices used in gastrointestinal and lung procedures.

The company on Tuesday reported greater sales from its heart rhythm device business and its MedSurg business, which sells products used in endoscopic procedures as well as women's health items. Cardiovascular device sales fell, however. A year ago its net income was hurt by costs related to job cuts and litigation.

In the fourth quarter the company's net income rose to $108 million, or $0.08 per share, from $60 million, or $0.04 per share. Boston Scientific said it earned $0.21 per share excluding one-time costs, up from $0.18 per share in the fourth quarter of 2012. Revenue rose 1%, to $1.84 billion from $1.82 billion.

Analysts expected net income of $0.12 per share and $1.83 billion in revenue, according to FactSet.

Shares of Boston Scientific lost $0.41 cents, or 3.2%, to $12.60 in morning trading. The stock has climbed almost 70% over the last year and reached a five-year high of $14.08 in January.

The Natick, Mass., company said sales of heart rhythm devices rose 5% to $518 million. MedSurg revenue rose 9% to $613 million on greater sales of endoscopy equipment and neuromodulation pain while cardiovascular revenue fell 4% to $705 million.

A year ago Boston Scientific said it would cut up to 1,000 jobs in response to a new medical device tax from the U.S. health care overhaul, limited growth prospects in certain markets and pressure to cut prices on its products in other countries. The company said it wanted to cut annual spending by as much as $375 million in 2013.

For the full year Boston Scientific Corp. lost $121 million, or 9 cents per share. It lost $4.07 billion, or $2.89 per share, in 2012. Revenue fell 1 percent, to $7.14 billion from $7.25 billion.

The company said it expects to earn $0.35 to $0.40 per share in 2014. Excluding costs related to restructuring, divestitures and acquisitions, it forecast net income of $0.75 to %0.80 per share, and it is calling for revenue of $7.3 billion to $7.5 billion.

Analysts expect net income of $0.52 per share and $7.42 billion in revenue on average.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.